Sanjeev krishan - Latest News Update, Information, Photos & Videos on Sanjeev krishan at Lokmat Times

Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today announced that its subsidiary Glenmark Specialty S.A. in Switzerland and an affiliate of Bausch Health Compes Inc. have entered into an exclusive licensing agreement for the commercialization of Glenmark's innovative nasal spray RYALTRIS under review by Health Canada.Under the terms of the agreement, Glenmark will be responsible for regulatory approvals and supply of RYALTRIS for the Canadian market. Bausch Health, Canada will be responsible for the commercialization of RYALTRIS in the Canadian market, following regulatory approval. Glenmark will receive an upfront payment, launch & sales-based milestone payments in addition to royalties and supply price from sales of RYALTRIS.RYALTRIS (Olopatadine Hydrochloride 665 mcg and Mometasone Furoate 25 mcg), is currently under review by Health Canada with a proposed indication for the treatment of seasonal allergic rhinitis in adults and children over 12 years of age.Commenting on the agreement, Sanjeev Krishan, President & Business Head - North America, Glenmark Pharmaceuticals, said, "We are pleased to partner with Bausch Health Canada, and recognize their strong foothold in the prescription and OTC market in Canada. This agreement will help us reach a larger patient population and extend the multiple benefits of RYALTRIS ™ to a significant market. Glenmark continues to build a strong portfolio in respiratory medicine, and RYALTRIS marks our first truly global brand launch to date.""We are pleased to add Ryaltris to our allergy product portfolio and eager to make it available to Canadian patients suffering from allergies," said Richard Lajoie, President of Bausch Health, Canada.In Canada, allergic rhinitis is estimated to afflict 25 per cent of the population and can have a significant impact on sleep, work and school performances. When approved in Canada, RYALTRIS will offer a fixed-dose combination of two different classes of medications in a convenient nasal spray presentation. A combination of intranasal antihistamines and intranasal corticosteroids may be beneficial and provide an additive effect on efficacy, resulting in superior relief of seasonal allergic rhinitis symptoms compared with monotherapyii.This story is provided by PRNewswire. will not be responsible in any way for the content of this article. (/PRNewswire)( With inputs from ANI )Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Home

City

Latest News

Cricket

LT Premium

National

International

Maharashtra

Opinions

Chhatrapati Sambhajinagar

Nagpur

Entertainment

Photos

Business

Technology

Sports

Lifestyle

Social Viral

Lokmat Games

Health

Pahalgam Terror Attack

Tahawwur Rana

IPL 2025

CM Devendra Fadnavis

Mumbai Local

Weather Update

Sanjeev Krishan, NewsFOLLOW

Sanjeev krishan, Latest News

Technology :PwC India announces to invest over Rs 600 cr towards employees' wellbeing

New Delhi, April 17 PwC India on Monday said it is committed to invest over Rs 600 crore ... ...

Business :Glenmark Pharmaceuticals receives ANDA approval for Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials

Glenmark Pharmaceuticals Ltd (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Arformoterol Tartrate Inhalation Solution, 15 mcg/2 mL, Unit-Dose Vials, the generic version of BROVANA®1 Inhalation So ...

Business :Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg

Glenmark Pharmaceuticals Limited (Glenmark) has launched Rufinamide Tablets USP, 200 mg and 400 mg, a therapeutic equivalent of Banzel® Tablets, 200 mg and 400 mg of Eisai, Inc. ...

Business :Glenmark and Bausch Health join hands to commercialise RYALTRIS nasal spray in Canada

Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, today announced that its subsidiary Glenmark Specialty S.A. in Switzerland and an affiliate of Bausch Health Companies Inc. have entered into an exclusive licensing a ...